Show simple item record

dc.contributor.authorAhmadi, H
dc.contributor.authorJamshidi, AR
dc.contributor.authorMahmoudi, M
dc.contributor.authorCuzzocrea, S
dc.contributor.authorFattahi, MJ
dc.contributor.authorBarati, A
dc.contributor.authorRehm, BHA
dc.contributor.authorMatsuo, H
dc.contributor.authorMirshafiey, A
dc.date.accessioned2018-04-19T01:10:37Z
dc.date.available2018-04-19T01:10:37Z
dc.date.issued2017
dc.identifier.issn1570-1638
dc.identifier.doi10.2174/1570163814666170321113059
dc.identifier.urihttp://hdl.handle.net/10072/373400
dc.description.abstractObjective: To investigate the inhibitory effect of β-D-mannuronic acid (M2000) on anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), antidouble strand DNA (anti-dsDNA) and acute phase reactants in rheumatoid arthritis (RA) patients. Methods: The study included 40 patients with RA who had an inadequate response to conventional therapy (identifier: IRCT2014011213739N2). The patients were permitted to continue the conventional therapy excluding NSAIDs. 21 of them were treated orally by M2000 at a dose of 500 mg twice daily for 12 weeks and the others did not. Serum samples were collected at baseline, 4 weeks and 12 weeks after treatment and were tested for the serum level of anti-CCP and anti-dsDNA antibodies using enzyme linked immunosorbent assay. The serum level of RF and C-reactive proteins (CRP) was determined by the immunoturbidimetric assay, respectively. Results: At baseline, all patients in the M2000 treated group and the control group were positive for anti-CCP, RF. moreover, 4 of 21 (19%) in the M2000 treated group and 2 of the 19 (10.5%) patients in the control group were positive for anti-dsDNA antibodies, respectively. The serum levels of anti-CCP, RF and anti-dsDNA were decreased significantly after M2000 therapy (p<0.001, p<0.001 and p<0.001, respectively). The reduction in the level of anti-CCP was positively correlated with disease activity, swollen joint count and CRP. Furthermore, the level of inflammatory markers ESR and CRP decreased significantly after M2000 therapy (p<0.001 and p<0.004, respectively). Conclusion: M2000 shows inhibitory effect on anti-CCP, RF, anti-dsDNA antibodies and acute phase reactants in RA patients.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBentham Science Publishers Ltd
dc.relation.ispartofpagefrom206
dc.relation.ispartofpageto214
dc.relation.ispartofissue3
dc.relation.ispartofjournalCurrent Drug Discovery Technologies
dc.relation.ispartofvolume14
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences not elsewhere classified
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode321499
dc.titleThe Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorRehm, Bernd


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record